Search

Frank C Borriello

from Winchester, MA
Age ~62
Get Report
Also known as:
Francescopaolo S Borriello, Frank S Borriello, Frances C Borriello, Frances S Borriello, Francesco Paolo Borriello, A Borriello, O Borriello
Phone and address:
3 Greeley Rd, Winchester, MA 01890
Related to:
Christopher Borriello, 37
Connected to:
Gloria Borriello, 41Jared C Borriello, 42Kellie M Borriello, 67Steve Borriello, 92Angela M Borrillo, 60Sandra J Borring, 53Alexandra J Borris, 33Daniel Borris, 63Demetrius S Borris, 45Jerome T Borris, 41

Frank Borriello Phones & Addresses

  • 3 Greeley Rd, Winchester, MA 01890
  • Cambridge, MA
  • Brookline, MA
  • Waltham, MA
  • Seattle, WA
  • Brooklyn, NY

Work

Company: Moerae matrix Sep 2016 to Mar 2018 Position: Fractional - cbo

Education

Degree: Doctor of Medicine, Doctorates, Doctor of Philosophy School / High School: Albert Einstein College of Medicine 1983 to 1991 Specialities: Biology, Immunology

Skills

Business Development • Clinical Development • Competitive Analysis • Financial Analysis • Research • Biopharmaceuticals • Biotechnology • Immunology • Business Strategy

Interests

Boating • Kids • Cooking • Exercise • Electronics • Outdoors • Home Improvement • Reading • Gourmet Cooking • Music • Sports • Camping • Travel • Movies • Home Decoration

Industries

Biotechnology

Resumes

Resumes

Frank Borriello Photo 1

Chief Executive Officer

View page
Location:
3 Greeley Rd, Winchester, MA 01890
Industry:
Biotechnology
Work:
Moerae Matrix Sep 2016 - Mar 2018
Fractional - Cbo
Alloplex Biotherapeutics Sep 2016 - Mar 2018
Chief Executive Officer
Baxalta May 2015 - Sep 2016
Vice President, Head of Search and Evaluation
Fb Biotech Consulting May 2015 - Sep 2016
Biotechnology Consultant
Baxter International Inc. Aug 2014 - Apr 2015
Global Business Development - Search and Evaluation
Education:
Albert Einstein College of Medicine 1983 - 1991
Doctor of Medicine, Doctorates, Doctor of Philosophy, Biology, Immunology New York University 1979 - 1983
Bachelors, Bachelor of Science, Chemistry
Skills:
Business Development
Clinical Development
Competitive Analysis
Financial Analysis
Research
Biopharmaceuticals
Biotechnology
Immunology
Business Strategy
Interests:
Boating
Kids
Cooking
Exercise
Electronics
Outdoors
Home Improvement
Reading
Gourmet Cooking
Music
Sports
Camping
Travel
Movies
Home Decoration

Business Records

Name / Title
Company / Classification
Phones & Addresses
Frank Borriello
Owner
Vertigo
Night Clubs
126 State St, Boston, MA 02109
(617) 723-7277
Frank Borriello
Owner
Fab Assoc
Whol Industrial Equipment
173 Playstead Rd, Medford, MA 02155
(781) 395-6263
Frank Borriello
President, Director
Broad St Variety
Ret News Dealer/Newsstand Ret Tobacco Products · Ret Tobacco Products Ret News Dealer/Newsstand
5 Broad St, Boston, MA 02109
(617) 248-8819
Frank J. Borriello
President
BOSTON ENTERTAINMENT GROUP, INC
126 State St, Boston, MA 02109
165 Locksley Rd, Lynnfield, MA 01940
Frank J. Borriello
President
BROAD STREET ENTERPRISES, INC
5 Broad St, Boston, MA 02109
5 Cider Ml Rd, Lynnfield, MA 01940
Frank Borriello
Manager
BIOTECH HORIZONS ASSET MANAGEMENT LLC
3 Greeley Rd, Winchester, MA 01890
Frank Borriello
Owner
Vertigo Lounge & Nightspot
Drinking Place
126 State St, Boston, MA 02109
(617) 723-7277

Publications

Us Patents

Allogenic Tumor Cell Vaccine

View page
US Patent:
20200330596, Oct 22, 2020
Filed:
Jun 11, 2020
Appl. No.:
16/899318
Inventors:
- Woburn MA, US
Frank Borriello - Winchester MA, US
Assignee:
ALLOPLEX BIOTHERAPEUTICS, INC. - Woburn MA
International Classification:
A61K 39/395
A61K 39/00
A61P 35/00
Abstract:
The described invention provides allogeneic tumor cell vaccines comprising tumor cell lines or tumor cell line variants that are genetically engineered to express a core group of three immunomodulatory molecules, and optionally additional R immunomodulatory polypeptides for induction of one or more subpopulations of PBMCs to proliferate in response to the expressed immunomodulatory molecules and to then enter an effector phase for killing of tumor cells. According to some embodiments, the tumor cell vaccine candidate can induce an immune response in the recipient cancer patient that cross reacts with the patient's own (autologous) tumor cells, the effects of which are sufficient to result in enhanced anti-tumor immunity contributing to the increased survival of a vaccinated patient cohort compared to a matched unvaccinated patient cohort.

Compositions And Methods For In Vitro Activation And Expansion Of Serial Killer T Cell Populations And Passive Immunization Of A Cancer Patient With Tumor Cell Killing Cells

View page
US Patent:
20200102538, Apr 2, 2020
Filed:
Oct 22, 2019
Appl. No.:
16/660442
Inventors:
- Winchester MA, US
Frank Borriello - Winchester MA, US
International Classification:
C12N 5/0783
A61K 35/17
A61K 45/06
A61P 35/00
C07K 16/18
A61K 39/395
C07K 14/535
A61K 38/19
C07K 14/52
C07K 14/705
A61K 38/17
C07K 14/525
Abstract:
The described invention provides a method for in vitro immunoactivation of mononuclear cells by contact with one or more populations of engineered leukocyte stimulator cells genetically engineered to express a core of 3 essential immunomodulator peptides, and optionally additional R immunomodulator peptides, and use of a cell product comprising the expanded and activated mononuclear cell population comprising one or more subpopulations of cytotoxic serial killer cells for passive immunization of a cancer patient not currently under the influence of an immunosuppressive regimen.

Allogenic Tumor Cell Vaccine

View page
US Patent:
20180185463, Jul 5, 2018
Filed:
Nov 22, 2017
Appl. No.:
15/821105
Inventors:
- Winchester MA, US
Frank Borriello - Winchester MA, US
International Classification:
A61K 39/00
A61P 35/00
Abstract:
The described invention provides a tumor cell vaccine comprising genetically modified tumor cell line of a particular tumor type that stably expresses high levels of two or more immunomodulators. According to some embodiments, an immunogenic amount of the tumor cell line variants may be selected for concomitant expression of two or more of recombinant membrane expressed IgG1, CD40L, TNF-alpha, as well as membrane and soluble forms of GM-CSF, and Flt-3L peptides that are effective to elicit an anti-tumor immune response compared to the parent unmodified tumor cell line as measured in vitro by a one-way mixed lymphocyte tumor reaction assay using human peripheral blood mononuclear cells and the genetically modified allogeneic cell vaccine candidate. According to some embodiments, the tumor cell vaccine candidate will induce an immune response in the recipient cancer patient that cross reacts with the patient's own (autologous) tumor cells, the effects of which will be sufficient to result in enhanced anti-tumor immunity contributing to the increased survival of a vaccinated patient cohort compared to a matched unvaccinated patient cohort.
Control profile
Frank C Borriello from Winchester, MA, age ~62 Get Report